Vivani Receives Approval for SLIM-1 Clinical Trial in Australia

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Jun 25 2026

0mins

VANI+18.52%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Clinical Trial Launch: Vivani Medical has received approval from Bellberry in Australia to initiate the SLIM-1 trial for NPM-139, expected to commence in mid-2026, marking a significant advancement in the biopharmaceutical sector and potentially accelerating drug development.
Trial Design Details: SLIM-1 will evaluate the safety and tolerability of low-dose NPM-139 (semaglutide NanoPortal implant) compared to Wegovy, involving 10 obese or overweight participants over a four-week duration, aimed at providing critical data for future studies.
Market Demand Expectations: CEO Adam Mendelsohn indicated strong market demand for miniature, reversible GLP-1 implant technology, with Vivani committed to meeting this need and advancing the clinical program for NPM-139 to enhance patient adherence to medication.
Future Development Plans: While SLIM-1 is underway, Vivani is preparing for SLIM-2, which will focus on dose-ranging efficacy trials pending successful results from SLIM-1, further accelerating the development timeline for NPM-139.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VANI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on VANI

Wall Street analysts forecast VANI stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.350

Low

4.00

Averages

4.00

High

4.00

Current: 1.350

Low

4.00

Averages

4.00

High

4.00

Lake Street

initiated

2026-06-23

Reason

Lake Street

Price Target

AI Analysis

2026-06-23

initiated

Reason

Lake Street initiated coverage of Vivani Medical with a Buy rating and $4 price target. One of the potential unmet needs in the weight management market is a longer-acting formulation to help patients tackle adherence issues that plague the GLP-1 space, says the analyst, who notes Vivani is taking on the adherence challenge with a long-acting implant technology that would deliver a steady dose of drug for up to 12 months. The firm, which anticipates the initiation and completion of a Phase 1 study of NPM-139, a semaglutide-containing implant, this year, believes a positive readout from the SLIM-1 study will set the company on \"a path toward clinical success and potential value-driving corporate development.\"

H.C. Wainwright

Yi Chen

Buy

downgrade

2026-03-31

Reason

H.C. Wainwright

Yi Chen

Price Target

2026-03-31

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Vivani Medical to $3.50 from $4 and keeps a Buy rating on the shares after the company recently reported its 2025 results, citing an increased share count for the firm's lowered target. The firm believes NPM-139 is uniquely positioned to potentially offer efficacy comparable to Wegovy while requiring only once or twice yearly administration, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VANI

Unlock Now

About VANI

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Vivani Medical Partners with Novo Nordisk for Semaglutide Implant Evaluation

1 day agoNASDAQ.COM

New Agreement: Vivani Medical has entered into a partnership with Novo Nordisk to evaluate its NPM-139 semaglutide implant for chronic weight management, marking a significant collaboration in the biopharmaceutical sector.
Clinical Trial Plans: Vivani expects to initiate a Phase 1 randomized clinical trial for NPM-139 in mid-2026, comparing its safety and tolerability against Wegovy injections, which will support subsequent Phase 2 dose-ranging studies.
Technological Innovation: NPM-139 is a miniature ultra-long-acting semaglutide implant utilizing Vivani's NanoPortal platform technology, designed to offer patients a convenient treatment option that caters to the demand for annual or biannual therapies.
Market Reaction: In pre-market trading on Nasdaq, Vivani's shares fell 1.54% to $1.32, while Novo Nordisk's shares rose 2.05% to $50.27, reflecting cautious optimism in the market regarding the new partnership.

Vivani Medical Partners with Novo Nordisk to Evaluate NanoPortal Implant for Semaglutide

1 day agoseekingalpha

Strategic Partnership: Vivani Medical (VANI) has entered into an agreement with Novo Nordisk (NVO) to evaluate its NanoPortal implant NPM-139 for the long-term administration of semaglutide, marketed as Wegovy for weight loss, indicating Novo Nordisk's interest in Vivani's technology.
Clinical Trial Plans: The NPM-139, based on the NanoPortal platform, is currently undergoing studies for chronic weight management, with a Phase 1 trial expected to begin in mid-2026 to compare the implant against Wegovy injections, aiming to provide patients with a more convenient weight loss treatment option.
Market Potential: Vivani's implant is anticipated to offer patients a once or twice-yearly treatment option for weight loss therapies, which could revolutionize the existing weight management market by enhancing patient adherence and treatment outcomes.
Industry Outlook: This collaboration not only showcases Vivani's technological capabilities in the MedTech sector but also opens new avenues for Novo Nordisk's expansion in the weight loss drug market, reflecting a joint effort to address the growing obesity crisis.

Vivani Signs New Agreement with Novo Nordisk for NPM-139 Evaluation

1 day agoNewsfilter

New Agreement Signed: Vivani Medical has signed an agreement with Novo Nordisk to allow the latter to evaluate NPM-139, a semaglutide drug implant for chronic weight management, indicating Novo Nordisk's interest in Vivani's technology and potentially paving the way for future collaboration.
Technology Platform Utilization: NPM-139 leverages Vivani's NanoPortal™ platform technology, aiming to provide convenient treatment options for patients who prefer once or twice-yearly treatments, thereby enhancing patient adherence and treatment outcomes.
Clinical Trial Plans: Vivani expects to initiate a Phase 1 randomized clinical trial for NPM-139 in mid-2026, comparing its safety and tolerability with Wegovy® injections, with successful results supporting a subsequent Phase 2 dose-ranging study.
Market Potential Outlook: Vivani CEO Adam Mendelsohn stated that this agreement reinforces confidence in the market opportunity for GLP-1 implants, indicating the company's strategic positioning in chronic disease treatment, which may lay the groundwork for future growth.

ClearOne's Strategic Shift and Merger with Cortigent

6 days agostocktwits

Strategic Pivot: ClearOne divested its legacy assets to Biamp in October last year, successfully pivoting into the medical technology sector, with former shareholders retaining approximately 12.7% to 14.4% of the new entity, indicating potential in the new market.
Reverse Merger Agreement: The announcement of a reverse merger with Cortigent, a unit of Vivani Medical, led to a more than 170% surge in CLRO stock, reflecting strong market recognition and investor optimism regarding the new business model.
Terms of the Deal: Under the agreement, Vivani will receive 12.5 million shares of ClearOne, gaining control of 59.4% to 67.5% of the combined entity, with Cortigent becoming the surviving entity, marking a new beginning for ClearOne in the medical technology field.
Funding Plan: ClearOne aims to raise up to $15 million concurrently with the deal's closing, providing a strong foundation for the combined company to advance its product pipeline and further solidify its market position.

Vivani Medical Appoints August Moretti to Board of Directors

Jun 26 2026Newsfilter

New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139 and leveraging NanoPortal™ technology.
Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance for the company's merger, reflecting the company's ongoing adaptability and leadership evolution.
Technological Development Strategy: Vivani is leveraging its proprietary NanoPortal™ technology to develop ultra-long-acting drug implants aimed at addressing medication adherence issues for chronic disease patients, which is expected to significantly enhance patient treatment experiences.
Market Potential: The company is developing GLP-1 based implants to tackle metabolic diseases, including obesity and type-2 diabetes, which are anticipated to provide patients with more stable drug delivery, thereby enhancing market competitiveness.